These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29730987)

  • 1. Stigma associated with medication treatment for young adults with opioid use disorder: a case series.
    Hadland SE; Park TW; Bagley SM
    Addict Sci Clin Pract; 2018 May; 13(1):15. PubMed ID: 29730987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Buprenorphine to Treat Opioid Use Disorder.
    Bartholow LAM; Pope J
    J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.
    Andrilla CHA; Moore TE; Patterson DG
    J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming medication stigma in peer recovery: A new paradigm.
    Krawczyk N; Negron T; Nieto M; Agus D; Fingerhood MI
    Subst Abus; 2018; 39(4):404-409. PubMed ID: 29432086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underutilization of medications to treat opioid use disorder: What role does stigma play?
    Allen B; Nolan ML; Paone D
    Subst Abus; 2019; 40(4):459-465. PubMed ID: 31550201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
    Holbrook AM
    Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stigma from the Viewpoint of the Patient.
    Woods JS; Joseph H
    J Addict Dis; 2015; 34(2-3):238-47. PubMed ID: 26076048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interest in prescribing buprenorphine among resident and attending physicians at an urban teaching clinic.
    James JR; Gordon LM; Klein JW; Merrill JO; Tsui JI
    Subst Abus; 2019; 40(1):11-13. PubMed ID: 29578857
    [No Abstract]   [Full Text] [Related]  

  • 13. Physicians' experiences with buprenorphine: A qualitative study of motivations for becoming X waivered and barriers to and facilitators of prescribing the medication for opioid use disorder.
    McCollum CG; Eaton E; Creger T; Lee A; Gagnon K; Li L
    Drug Alcohol Depend; 2023 Mar; 244():109777. PubMed ID: 36680808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine.
    Andrilla CHA; Jones KC; Patterson DG
    J Rural Health; 2020 Mar; 36(2):187-195. PubMed ID: 31650634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary.
    McElrath K
    Subst Use Misuse; 2018 Jan; 53(2):334-343. PubMed ID: 28862903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing stigma through education to enhance Medication-Assisted Recovery.
    Woods JS; Joseph H
    J Addict Dis; 2012; 31(3):226-35. PubMed ID: 22873184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
    Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
    Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intervention stigma: How medication-assisted treatment marginalizes patients and providers.
    Madden EF
    Soc Sci Med; 2019 Jul; 232():324-331. PubMed ID: 31125801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.